Clinical Trial Testing the efficacy and Safety of Two Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer

Update Il y a 4 ans
Reference: EUCTR2014-005067-32

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Evaluate the efficacy of ramucirumab 12 mg/kg versus placebo, both in combination with paclitaxel, in terms of PFS


Inclusion criteria

  • Second-Line Metastatic or Locally Advanced, Unresectable
  • Gastric or Gastroesophageal Junction Adenocarcinoma